SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant attention as investors anticipate imminent positive Phase 3 trial results for its GPS cancer treatment, with the ongoing "silence" from management interpreted as a strong signal of prolonged patient survival and potential M&A. The bullish community is aggressively battling shorts to break key resistance levels, expecting a substantial revaluation and short squeeze even as the broader market declines.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions and disruptions to the Strait of Hormuz send crude oil prices soaring, fueling a broader rally in the energy sector. While other oil stocks experience significant gains, the community remains divided on INDO's suppressed price action, with some anticipating a manipulated dip before a major surge and others expressing frustration over its underperformance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is capturing market attention as the photonics sector heats up, fueled by Nvidia's strategic investments and broader industry recognition of optical interconnects as essential for AI scaling. The community is actively discussing POET's disruptive wafer-scale technology and potential for significant hyperscaler partnerships, making it a standout performer in a challenging market.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is trending amidst rising oil prices driven by escalating geopolitical tensions, which is fueling a significant short squeeze. The trading community is actively debating the stock's surprising surge despite a recent private placement at a much lower valuation.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a strong Q4 revenue beat and optimistic guidance projecting future multi-billion dollar revenues, with the company confirming full funding for its satellite constellation and no immediate dilution plans. The community is buzzing with excitement over these positive updates and the stock's impressive resilience amid broader market weakness.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is experiencing a sharp post-earnings sell-off despite strong Q4 results, fueled by cautious forward guidance and executive departures, leading to a divided community debate. Investors are actively discussing whether the substantial dip offers a compelling buying opportunity, given its role in AI infrastructure, or if the software sector's re-evaluation will push the stock lower.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending with high anticipation for its upcoming earnings report, as investors fiercely debate its valuation and resilience in the Agentic AI space amidst strong competition. Bulls anticipate a significant short squeeze and fundamental strength, while bears remain concerned about insider selling and potential commoditization.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending after reporting a better-than-expected earnings report and providing an upbeat full-year forecast, sparking community discussion around its attractive valuation relative to retail peers and the potential for a strategic turnaround under new leadership despite recent comparable sales declines.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to extreme market volatility and a swift "V-rally" observed amid escalating Middle East geopolitical tensions. Community chatter is sharply divided between those celebrating a massive short squeeze and others accusing the market of being "rigged" against a backdrop of potential oil supply disruptions.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors eagerly await its full-year 2025 earnings, with many anticipating record revenue and improved profitability from its growing AI infrastructure and data center business. The community is actively debating if strong fundamentals will finally overcome historical price volatility and high short interest, potentially leading to a significant upward move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


The biotech sector remains a hotbed for retail investor interest, with over 3.4 million users following these stocks on Stocktwits. Last week, the below three companies saw the highest increases in retail following:Kairos Pharma Ltd. (+83%)Kairos Pharma, a clinical-stage biopharmaceutical company focused on cancer therapeutics, saw the most spike in retail chatter.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.Retail interest soared last week after Kairos broke key resistance levels and secured crucial investments.&nbsp;The stock surged nearly 120% last Monday following positive comments from CEO John Yu at an investor healthcare summit.&nbsp;Additionally, the company completed a $3.5 million PIPE transaction, which the CEO said would ensure the continued progress of its clinical trials and asset development.&nbsp;Despite these gains, Kairos has lost 21% of its value since its NYSE debut in September.OS Therapies Inc. (+39%)Shares of OS Therapies jumped after the company reported positive clinical trial data for its OST-HER2 candidate, which targets a rare bone cancer that spreads to the lungs.&nbsp;Following the announcement, Maxim analyst Jason McCarthy raised the firm’s price target to $15 from $8, maintaining a ‘Buy’ rating.&nbsp;The data has positioned OS Therapies to meet with the FDA by the end of the first quarter of 2025 to discuss the possibility of filing for accelerated approval.The company is focused on oncology treatments, with OST-HER2 being its lead immunotherapy asset. It leverages listeria bacteria’s immune-stimulatory effects to target the HER2 protein in cancer cells.AEON Biopharma Inc. (+19%)AEON Biopharma is a company developing the proprietary botulinum toxin complex ABP-450, a biosimilar to Evolus’ Jeuveau, approved for cosmetic use, but AEON is developing it for medical indications.&nbsp;The company’s manufacturing partner, Daewoong, produces ABP-450 in FDA-approved facilities under current Good Manufacturing Practices (cGMP).Although there were no specific catalysts driving the recent spike, it appears that retail investors were buying the dip after the company priced a public offering to raise $20 million earlier this month, which had caused the stock to slide.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

Cryptocurrencies were on fire last week and therefore it should come as no surprise that Stocktwits users turned their attention increasingly toward the crypto and allied space. Among the 10 stocks that saw the biggest increase in watcher count on Stocktwits, four were cryptocurrencies and two were Bitcoin miners.Here’s a compilation of stocks/cryptos that were closely followed by retail last week along with their watcher count:<ul><li>Dogecoin (<a class="mention" data-mention="$DOGE.X" data-symbol-id="DOGE.X" href="https://stocktwits.com/symbol/DOGE.X" target="_blank">$DOGE.X</a>) (336,178)</li><li>SPDR S&amp;P 500 ETF Trust (<a class="mention" data-mention="$SPY" data-symbol-id="SPY" href="https://stocktwits.com/symbol/SPY" target="_blank">$SPY</a>) (537,941)</li><li>Bitcoin (<a class="mention" data-mention="$BTC.X" data-symbol-id="BTC.X" href="https://stocktwits.com/symbol/BTC.X" target="_blank">$BTC.X</a>) ($601,174)</li><li>Ripple (<a class="mention" data-mention="$XRP.X" data-symbol-id="XRP.X" href="https://stocktwits.com/symbol/XRP.X" target="_blank">$XRP.X</a>) (174,221)</li><li>Innovation Beverage Group Ltd. (<a class="mention" data-mention="$IBG" data-symbol-id="IBG" href="https://stocktwits.com/symbol/IBG" target="_blank">$IBG</a>) (1,260)</li><li>Tesla, Inc. (<a class="mention" data-mention="$TSLA" data-symbol-id="TSLA" href="https://stocktwits.com/symbol/TSLA" target="_blank">$TSLA</a>) (980,127)</li><li>PepeCoin (<a class="mention" data-mention="$PEPE.X" data-symbol-id="PEPE.X" href="https://stocktwits.com/symbol/PEPE.X" target="_blank">$PEPE.X</a>) (17,692)</li><li>Kairos Pharma Ltd. (<a class="mention" data-mention="$KAPA" data-symbol-id="KAPA" href="https://stocktwits.com/symbol/KAPA" target="_blank">$KAPA</a>) (1,076)</li><li>Mara Holdings Ltd. (<a class="mention" data-mention="$MARA" data-symbol-id="MARA" href="https://stocktwits.com/symbol/MARA" target="_blank">$MARA</a>) (147,043)</li><li>BTC Digital Ltd. (<a class="mention" data-mention="$BTCT" data-symbol-id="BTCT" href="https://stocktwits.com/symbol/BTCT" target="_blank">$BTCT</a>) (4,228)</li></ul>Dogecoin:&nbsp;Dogecoin, a meme coin, was on a tear last week as it went past the $0.40 level before pulling back since the mid-week. The retail crowd are factoring in the meme crypto breaking above its May 2021 highs of $0.74.&nbsp;SPY: The SPY, which is an exchange-traded fund that tracks the broader S&amp;P 500 Index, closed at a record high of $598.76 last Monday. The ETF has come under pressure since then amid fears that the Federal Reserve may give rate cuts a pass at the December meeting. As the year draws to the close and the market enters a seasonally strong period, retail interest in the ETF has been on the rise.Bitcoin:&nbsp;Donald Trump’s victory in the Nov. 5 election has set in motion broad-based buying in the crypto space amid hopes his policies would be more crypto-friendly. Bitcoin rose to a record high past the $93K level last week before pulling back to the $90K level. It has started the new week on a firmer note and has rebounded toward the $92K level.Ripple: Blockchain company Ripple’s native coin, the XRP, rallied past the $1 against the U.S. dollar last week amid hopes that SEC Chair Gary Gensler would be replaced. The current SEC Chair has gone after Ripple and the regulator has an ongoing lawsuit against the company for raising&nbsp;more than $1.3 billion in 2013 by selling XRP in an unregistered public offering.&nbsp;Innovation Beverage: Australian beverage maker Innovation Beverage, which sells domestically and in the U.S., saw its Nasdaq-listed shares jump 40% last week. The gains have been accompanied by a surge in volumes traded. Following a recent initial public offering, the stock was listed on Sept. 26.Retailers on the Stocktwits see scope for further upside as some of them pointed to the stock being a subject of interest on WallStreetBets reddit forum.Tesla: Trump’s victory led to a surge in Tesla shares past the $350 mark (on an intraday basis) last week but they have pulled back since then. Tesla investors view Elon Musk’s closeness to Trump as a positive for the stock even as the company’s electric-vehicle business is awaiting an inflection.PepeCoin:&nbsp;PepeCoin, another meme coin that has generated interest among retailers, more than doubled in the seven sessions that ended Nov. 9, coinciding with the presidential election. It topped $5 on Nov. 9 but has retreated since then and traded around the $4 mark.&nbsp;&nbsp;Kairos Pharma: Shares of California-based nano-cap oncology-focused clinical-stage biotech Kairos surged past $2 on Tuesday on above-average volume, with retail frenzy propping up the stock.. The buying continued in the next session before moderating. Kairos is a newly public company and was listed in mid-September.&nbsp;Mara Holdings:&nbsp;Bitcoin miner Mara’s shares plunged on Wednesday after the company reported a third-quarter revenue miss. Retail, however, is betting on the company in the hopes that the Bitcoin rally could help the miner stage a comeback.BTC Digital:&nbsp; BTC Digital shares soared over 950% to $19.27 in the week ended Nov. 15, rising from under $2 in the previous week. Retailers on the Stocktwits are bullish on the bitcoin miner.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/10-stocks-with-biggest-message-volume-on-stocktwits/cJ4HwPIRQP">10 Most Active Stocks On Stockwits Last Week With Message Volume Spurt</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Trump trades have continued to evince retail attention. 

10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Kairos Pharma Ltd.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $CRWD earnings on Tuesday?

Current Price	$0.6356
Prev Close	$0.61
Open	$0.595
Dividend Yield	0.00%
50-Day Moving Average	$0.7114
Beta	0.83
Avg. Volume	1.32M
PE Ratio	-2.02

52-Week High	$2.11
52-Week Low	$0.40
Market Capitalization	$12.7M
EPS (Annual)	-$0.1895
Price to Book	1.66
Revenue Per Employee	$0.00

KAPA
Kairos Pharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest KAPA News

KAPAKairos Pharma Ltd.